Atlanta | April 6–8, 2024 | Booth 1923
DCRI experts are excited to share and discuss the latest scientific developments in cardiology with our partners from around the globe at the American College of Cardiology 73rd Annual Scientific Session & Expo April 6–8 in Atlanta. Our faculty, fellows, and operational experts will showcase thought leadership and inspire peer providers to turn knowledge into clinical practice through late-breaking clinical trial sessions, presentations, panel discussions, and collaborator meetings. Click the links below to learn more about DCRI's presence at ACC.24.
Quick Links: DCRI Presentations | News from ACC | DCRI Expertise
Presentations
DCRI faculty and thought leaders will contribute to over 75 sessions this year including presentations, panel discussions, debates, mentorship events, and moderated poster sessions. We will cover topics ranging from interventional therapies, drug comparisons, professional equity, guideline adherence, and more.
Meet the Experts
AEGIS-II
Saturday, April 6 from noon-1 p.m. at DCRI Booth, no. 1923
Join co-investigators Thomas Povsic, MD, PhD, and John H. Alexander, MD, MHS, following the AEGIS-II late-breaking session to learn more about the study, its successful enrollment of 18,226 patients in 46 countries, and how the DCRI managed 193 U.S. sites with more than 1,800 high-risk acute MI patients, mainly during the COVID-19 pandemic.
V-INCLUSION
Monday, April 8 from 11 a.m.-noon at DCRI Booth, no. 1923
Speak with Neha Pagidipati, MD, MPH, about her upcoming study. V-INCLUSION will recruit approximately 1,440 racially, ethnically, and geographically diverse participants who have historically been underrepresented in clinical research. The trial will measure the effectiveness of usual care + inclisiran in those with established ASCVD or those at high risk.
DCRI Late-Breaker and Featured Presentations
Saturday, April 6, 2024
9:50–10:02 a.m. | Hall B-1 Main Tent
402-10 — Empagliflozin After Acute Myocardial Infarction: Results Of The EMPACT-MI Trial with contributions from DCRI Faculty Schuyler Jones, MD, and Adrian Hernandez, MD, MHS
10:10–10:22 a.m. | Hall B-1 Main Tent
402-10 — CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results with contributions from DCRI Faculty John Alexander, MD, MHS, Renato D. Lopes, MD, PhD, FACC, and Thomas J. Povsic, MD, PhD
Sunday, April 7, 2024
10:00–10:10 a.m. | Hall B-1 Main Tent
406-10 — Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial with contributions from DCRI Experts Daniel Mark, MD, and Kevin Anstrom, PhD, MHS
12:15–1:30 p.m. | Hall B-1 Main Tent
407 — Featured Clinical Research II with DCRI Faculty Panelists Neha J. Pagidipati, MD, MPH, and Robert J. Mentz, MD
2:00–3:15 p.m. | Hall B-1 Main Tent
408 — Late-Breaking Clinical Trials Deep Dive I with DCRI Faculty Discussant Robert J. Mentz, MD
Monday, April 8, 2024
2:30–3:45 p.m. | Hall B-1 Main Tent
414 — Late-Breaking Clinical Trials Deep Dive II with DCRI Faculty Discussant Manesh Patel, MD
DCRI News from ACC.24
Check back on April 6, 2024, to read late-breaking news from DCRI at ACC.24!
ACC.24 Social Media
Stay connected with the following hashtag: #ACC24
Learn More About DCRI Expertise
Transforming the Future of CV Care
Learn why the world looks to the DCRI as the definitive leader in cardiovascular clinical research, implementation science, and education.
Beyond CV
DCRI expertise extends beyond cardiovascular research. Visit our DCRI At-A-Glance page to learn quick facts about the world's largest academic research organization.
DCRI Studies Recruiting Sites & Participants
The DCRI, together with its esteemed site community partners, is addressing clinical research challenges that will shape the future of medical care for years to come. Would you like to partner with the DCRI? View DCRI studies across therapeutic areas currently recruiting sites and/or participants.